RU2017120330A - Способ прогнозирования ответа на терапевтические агенты для лечения рака молочной железы и способ лечения рака молочной железы - Google Patents

Способ прогнозирования ответа на терапевтические агенты для лечения рака молочной железы и способ лечения рака молочной железы Download PDF

Info

Publication number
RU2017120330A
RU2017120330A RU2017120330A RU2017120330A RU2017120330A RU 2017120330 A RU2017120330 A RU 2017120330A RU 2017120330 A RU2017120330 A RU 2017120330A RU 2017120330 A RU2017120330 A RU 2017120330A RU 2017120330 A RU2017120330 A RU 2017120330A
Authority
RU
Russia
Prior art keywords
breast cancer
subject
classifier score
basal
androgen receptor
Prior art date
Application number
RU2017120330A
Other languages
English (en)
Russian (ru)
Other versions
RU2017120330A3 (enExample
Inventor
Эми Кристиан ПЭТЕРСОН
Хирдеш АППАЛ
Original Assignee
Медивэйшн Простейт Терапьютикс, Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медивэйшн Простейт Терапьютикс, Ллс filed Critical Медивэйшн Простейт Терапьютикс, Ллс
Publication of RU2017120330A publication Critical patent/RU2017120330A/ru
Publication of RU2017120330A3 publication Critical patent/RU2017120330A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
RU2017120330A 2014-12-12 2015-12-08 Способ прогнозирования ответа на терапевтические агенты для лечения рака молочной железы и способ лечения рака молочной железы RU2017120330A (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462091195P 2014-12-12 2014-12-12
US62/091,195 2014-12-12
US201562142504P 2015-04-03 2015-04-03
US62/142,504 2015-04-03
US201562167110P 2015-05-27 2015-05-27
US62/167,110 2015-05-27
PCT/US2015/064500 WO2016094408A1 (en) 2014-12-12 2015-12-08 Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer

Publications (2)

Publication Number Publication Date
RU2017120330A true RU2017120330A (ru) 2019-01-14
RU2017120330A3 RU2017120330A3 (enExample) 2019-07-24

Family

ID=55273509

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017120330A RU2017120330A (ru) 2014-12-12 2015-12-08 Способ прогнозирования ответа на терапевтические агенты для лечения рака молочной железы и способ лечения рака молочной железы

Country Status (15)

Country Link
US (3) US10196693B2 (enExample)
EP (2) EP3604556A1 (enExample)
JP (1) JP6735277B2 (enExample)
KR (1) KR20170095306A (enExample)
CN (1) CN107109488A (enExample)
AU (1) AU2015360767A1 (enExample)
BR (1) BR112017012142A2 (enExample)
CA (1) CA2970469A1 (enExample)
ES (1) ES2748005T3 (enExample)
IL (1) IL252587A0 (enExample)
MX (1) MX2017007707A (enExample)
RU (1) RU2017120330A (enExample)
SG (1) SG11201704425TA (enExample)
WO (1) WO2016094408A1 (enExample)
ZA (1) ZA201703904B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9517229B2 (en) 2011-07-29 2016-12-13 Medivation Prostate Therapeutics, Inc. Treatment of breast cancer
US20140243211A1 (en) 2013-02-28 2014-08-28 Indiana University Research & Technology Corporation Blood biomarkers for suicidality
BR112017012142A2 (pt) 2014-12-12 2018-01-02 Medivation Prostate Therapeutics Inc método para predição da resposta a agentes terapêuticos para o câncer de mama e método de tratamento de câncer de mama
AU2016274988A1 (en) 2015-06-12 2017-12-21 Indiana University Research & Technology Corporation Predicting suicidality using a combined genomic and clinical risk assessment
KR101966493B1 (ko) * 2016-06-27 2019-04-05 국립암센터 삼중음성유방암 예후 예측용 바이오마커
KR101896558B1 (ko) * 2016-11-21 2018-09-07 주식회사 젠큐릭스 유방암 환자의 예후 예측 방법
WO2018198927A1 (ja) * 2017-04-26 2018-11-01 日本電信電話株式会社 Ｎ×ｎ光スイッチ
CA3105451A1 (en) 2017-05-12 2018-11-15 Indiana University Research And Technology Corporation Precision medicine for treating and preventing suicidality
RU2648523C1 (ru) * 2017-05-22 2018-03-26 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") Способ прогнозирования исхода заболевания у больных люминальным в и трижды негативным раком молочной железы у пациенток, не получавших в неоадъювантном режиме химио- или гормонотерапию
AU2019268481B2 (en) * 2018-05-14 2025-04-03 Hinova Pharmaceuticals Inc. HC-1119 formulation, preparation method and use thereof
WO2020001473A1 (zh) * 2018-06-28 2020-01-02 复旦大学 小核仁核糖核酸snord33作为生物标记物用于制备检测试剂盒中的用途
CN109735625A (zh) * 2019-03-18 2019-05-10 马榕 乳头溢液在检测肿瘤相关基因中的应用
CN114334000B (zh) * 2021-12-28 2025-07-25 上海中医药大学 基于转录组图谱的组合药物生成方法、系统及存储介质
US20260043086A1 (en) * 2022-08-06 2026-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Predictive biomarker in avastin in colon cancer

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
JP2001521753A (ja) 1997-10-31 2001-11-13 アフィメトリックス インコーポレイテッド 成人臓器及び胎児臓器中の発現プロフィール
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6937713B1 (en) 1999-12-30 2005-08-30 At&T Corp. IP call forward profile
US7504222B2 (en) 2001-10-31 2009-03-17 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20070192880A1 (en) 2003-10-03 2007-08-16 University Of Rochester Horming response element binding transregulators
US20070059720A9 (en) 2004-12-06 2007-03-15 Suzanne Fuqua RNA expression profile predicting response to tamoxifen in breast cancer patients
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
NZ564223A (en) 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
CA2630974A1 (en) 2005-11-23 2007-05-31 University Of Utah Research Foundation Methods and compositions involving intrinsic genes
BRPI0709771B1 (pt) 2006-03-27 2022-01-25 The Regents Of The University Of California Composto e composição farmacêutica
NZ596260A (en) 2006-03-29 2013-05-31 Univ California Diarylthiohydantoin compounds
TWI469971B (zh) 2007-10-26 2015-01-21 Univ California 二芳基乙內醯脲類化合物
WO2009064738A2 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
WO2009114534A1 (en) 2008-03-14 2009-09-17 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
SI2297359T1 (sl) 2008-05-30 2014-05-30 The University Of North Carolina At Chapel Hill Profili genskega izraĹľanja za napovedovanje izida raka dojke
JP2012518661A (ja) 2009-02-24 2012-08-16 メディベイション プロステイト セラピューティクス， インコーポレイテッド 特定のジアリールヒダントインおよびジアリールチオヒダントイン化合物
EP2416657A4 (en) 2009-04-09 2012-09-05 Medivation Prostate Therapeutics Inc COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF
EP2425015B1 (en) 2009-04-29 2018-01-10 Ralph Wirtz A method to assess prognosis and to predict therapeutic success in cancer by determining hormone receptor expression levels
US8507195B2 (en) 2009-08-20 2013-08-13 The Regents Of The University Of Colorado MiRNAs dysregulated in triple-negative breast cancer
EP2473619A4 (en) 2009-09-03 2013-03-27 Scripps Research Inst METHOD FOR CATEGORIZING CIRCULATING TUMOR CELLS
WO2011044327A1 (en) 2009-10-07 2011-04-14 Medivation Prostate Therapeutics, Inc. Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds
JP5971769B2 (ja) 2011-03-15 2016-08-17 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル アントラサイクリン療法を用いて乳癌を処置する方法
US8781912B2 (en) 2011-03-15 2014-07-15 Opera Solutions, Llc Computer-based method and computer program product for setting floor prices for items sold at auction
US9517229B2 (en) 2011-07-29 2016-12-13 Medivation Prostate Therapeutics, Inc. Treatment of breast cancer
WO2013082440A2 (en) 2011-11-30 2013-06-06 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with taxane therapy
WO2014031164A1 (en) 2012-08-23 2014-02-27 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment
US9175291B2 (en) * 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
WO2014075067A1 (en) 2012-11-12 2014-05-15 Nanostring Technologies, Inc. Methods to predict breast cancer outcome
US10679730B2 (en) * 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
BR112017012142A2 (pt) 2014-12-12 2018-01-02 Medivation Prostate Therapeutics Inc método para predição da resposta a agentes terapêuticos para o câncer de mama e método de tratamento de câncer de mama

Also Published As

Publication number Publication date
US10196693B2 (en) 2019-02-05
US20160168646A1 (en) 2016-06-16
US11952634B2 (en) 2024-04-09
BR112017012142A2 (pt) 2018-01-02
CN107109488A (zh) 2017-08-29
US20190169697A1 (en) 2019-06-06
SG11201704425TA (en) 2017-06-29
KR20170095306A (ko) 2017-08-22
EP3604556A1 (en) 2020-02-05
WO2016094408A1 (en) 2016-06-16
IL252587A0 (en) 2017-07-31
ZA201703904B (en) 2019-12-18
EP3230471B1 (en) 2019-08-28
US11186876B2 (en) 2021-11-30
US20220056541A1 (en) 2022-02-24
JP2018504892A (ja) 2018-02-22
AU2015360767A1 (en) 2017-06-08
EP3230471A1 (en) 2017-10-18
MX2017007707A (es) 2018-03-06
CA2970469A1 (en) 2016-06-16
RU2017120330A3 (enExample) 2019-07-24
JP6735277B2 (ja) 2020-08-05
ES2748005T3 (es) 2020-03-12

Similar Documents

Publication Publication Date Title
JP2018504892A5 (enExample)
JP7013388B2 (ja) Ｈｄａｃ阻害剤とｐｄ－ｌ１阻害剤との組み合わせ療法
US11730736B2 (en) Anticancer agents
WO2017197153A1 (en) Combination therapies of hdac inhibitors pd-1 inhibitors
HRP20212033T1 (hr) Anti-lag-3 antitijela za liječenje hematoloških maligniteta
FI3377534T3 (fi) Keuhkosyövän hoito käyttäen anti-pd-1-vasta-aineen ja anti-ctla-4-vasta-aineen yhdistelmää
JP2014513136A5 (enExample)
RU2018103064A (ru) Комбинация ингибитора hdac и анти-pd-l1-антитела для лечения злокачественной опухоли
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
JP2017535534A (ja) がんを治療するための単独または併用療法におけるｃｃｒ５拮抗剤の使用
CN108779111B (zh) 结合脱氧胞苷激酶的化合物
MX2012012075A (es) Moleculas y metodos para usarlas para tratar enfermedades asociadas con ligandos erbb/erbb.
RU2013137380A (ru) Комбинация сиросингопина и митохондриальных ингибиторов для лечения рака и для иммуносупрессии
EP3720560A1 (en) Methods of treating cancer with plk4 inhibitors
RU2016148441A (ru) Способ лечения pr-положительного люминального а-типа рака молочной железы ингибитором pi3k пиктилисибом
Shao et al. Recent Progress on primary central nervous system lymphoma—from Bench to Bedside
AR085141A1 (es) Un metodo para prolongar la supervivencia de un aloinjerto renal, uso de un anticuerpo anti-cd200 para prolongar la supervivencia de aloinjertos
RU2488173C1 (ru) Способ создания биологической модели умеренного торможения роста опухоли и метастазов карциномы легких льюис с продолжительной циклофосфаниндуцированной лейкопенией у мышей
RU2017112998A (ru) Способ лечения солидного рака и/или его метастазов, предназначенные для этого медикаменты и способ прогнозирования клинического исхода лечения солидного рака и/или его метастазов
RU2532342C1 (ru) Способ прогнозирования рецидива рака вульвы
RU2015129366A (ru) Способы и композиции, относящиеся к лечению злокачественной опухоли
Nguyen et al. Occult colon cancer with initial cutaneous metastatic manifestation: PET/CT detection
RU2408082C1 (ru) Способ оценки сочетанного действия цитостатика и внешнего гамма-облучения в эксперименте
RU2488890C1 (ru) Способ моделирования хронической цитостатической миелосупрессии
Jin et al. OS12. 4. A AI-BASED HISTOPATHOLOGICAL CLASSIFICATION OF CENTRAL NERVOUS SYSTEM TUMOURS

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20191106